Karyopharm Therapeutics Inc. (KPTI)
After hours:
Chart Events
Performance Outlook
| Previous Close | 3.4900 |
| Open | 3.4600 |
| Bid | 3.5100 x 3200 |
| Ask | 3.5200 x 800 |
| Day's Range | 3.4350 - 3.6300 |
| 52 Week Range | 2.4500 - 8.6300 |
| Volume | |
| Avg. Volume | 2,701,306 |
| Market Cap | 397.378M |
| Beta (5Y Monthly) | -0.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
Karyopharm Therapeutics (NASDAQ:KPTI) shareholders have endured a 87% loss from investing in the stock three years ago
It's not possible to invest over long periods without making some bad investments. But really bad investments should be...
- Insider Monkey
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2022 Earnings Call Transcript
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2022 Earnings Call Transcript February 15, 2023 Operator: Good day. My name is Andrea, and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics Fourth Quarter and Full Year 2022 Financial Results Conference Call. . Please be advised that […]
- Motley Fool
Karyopharm Therapeutics (KPTI) Q4 2022 Earnings Call Transcript
At this time, I would like to welcome everyone to the Karyopharm Therapeutics, fourth-quarter and full-year 2022 financial results conference call. As you can see on Slide 5, Karyopharm was founded in 2008 as an innovation and patient-focused company, developing first-in-class, oral selective inhibitor of nuclear export, which target XPO1 to improve patient outcomes in cancer.
